# What After the First Propess

> **NCT02956785** · PHASE2 · TERMINATED · sponsor: **South Warwickshire NHS Foundation Trust** · enrollment: 85 (actual)

## Conditions studied

- Induction of Labor

## Interventions

- **DRUG:** 10 mg Dinoprostone; CTS, UK
- **DRUG:** 3 mg Dinoprostone vaginal tablet; Pfizer, UK
- **DRUG:** Aquacryl hydrogel rod; HPSRx Enterprises, USA

## Key facts

- **NCT ID:** NCT02956785
- **Lead sponsor:** South Warwickshire NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01
- **Primary completion:** 2022-11
- **Final completion:** 2022-11
- **Target enrollment:** 85 (ACTUAL)
- **Why stopped:** Inability to recruit more women because of the COVID-19 and staffing/resources issues
- **Last updated:** 2022-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02956785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02956785, "What After the First Propess". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02956785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*